Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

被引：90

作者：

Gardini, Andrea Casadei ^{[1
]}

Scarpi, Emanuela ^{[2
]}

Faloppi, Luca ^{[3
,4
]}

Scartozzi, Mario ^{[4
]}

Silvestris, Nicola ^{[5
]}

Santini, Daniele ^{[6
]}

de Stefano, Giorgio ^{[7
]}

Marisi, Giorgia ^{[8
]}

Negri, Francesca V. ^{[9
]}

Foschi, Francesco Giuseppe ^{[10
]}

Valgiusti, Martina ^{[1
]}

Ercolani, Giorgio ^{[11
,12
]}

Frassineti, Giovanni Luca ^{[1
]}

机构：

[1] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, Meldola, Italy

[2] IRST IRCCS, Unit Biostat & Clin Trials, Meldola, Italy

[3] Osped Gen Prov Macerata ASUR Marche AV3, Dept Med Oncol, Macerata, Italy

[4] Univ Hosp Cagliari, Dept Med Oncol, Cagliari, Italy

[5] Canc Inst Giovanni Paolo II, Med Oncol Unit, Bari, Italy

[6] Univ Campus Biomed, Dept Med Oncol, Via Alvaro del Portillo, Rome, Italy

[7] D Cotugno Hosp, Infect Dis & Intervent Ultrasound Unit, Naples, Italy

[8] IRST IRCCS, Biosci Lab, Meldola, Italy

[9] Univ Hosp, Med Oncol Unit, Parma, Italy

[10] AUSL Romagna, Faenza Hosp, DPT Internal Med, Forli, Italy

[11] AUSL Romagna, Morgagni Pierantoni Hospiatal, Dept Gen Surg, Forli, Italy

[12] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

来源：

ONCOTARGET | 2016年 / 7卷 / 41期

关键词：

systemic immune-inflammation index; inflammation; biomarker; hepatocellular carcinoma; neutrophil-to-lymphocyte ratio; TO-LYMPHOCYTE RATIO; CIRCULATING TUMOR-CELLS; PROGNOSTIC-FACTOR;

D O I：

10.18632/oncotarget.11565

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We evalueted a systemic immune-inflammation index (SII), neutrophil-to-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) with the aim to explored their prognostic value in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. 56 advanced HCC patients receiving sorafenib were available for our analysis. Lymphocyte, neutrophil and platelet were measured before beginning of treatment and after one month. Patient with SII >= 360 showed lower median PFS (2.6 vs. 3.9 months, P < 0.026) and OS (5.6 vs. 13.9 months, P = 0.027) with respect to patients with SII < 360. NLR >= 3 had a lower median PFS (2.6 vs. 3.3 months, P < 0.049) but not OS (5.6 vs. 13.9 months, P = 0.062) than those with NLR < 3. After adjusting for clinical covariates SII and NLR remained an independent prognostic factor for OS. The SII and NLR represent potential prognostic indicator in patients with advanced HCC treated with sorafenib.

引用

页码：67142 / 67149

页数：8

共 27 条

[1] Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Cheng, Ann-Lii
Kang, Yoon-Koo
Chen, Zhendong
Tsao, Chao-Jung
Qin, Shukui
Kim, Jun Suk
Luo, Rongcheng
Feng, Jifeng
Ye, Shenglong
Yang, Tsai-Sheng
Xu, Jianming
Sun, Yan
Liang, Houjie
Liu, Jiwei
Wang, Jiejun
Tak, Won Young
Pan, Hongming
Burock, Karin
Zou, Jessie
Voliotis, Dimitris
Guan, Zhongzhen
[J]. LANCET ONCOLOGY, 2009, 10 (01) : 25 - 34
[2] CANCER Inflammation lights the way to metastasis
Coffelt, Seth B.
de Visser, Karin E.
[J]. NATURE, 2014, 507 (7490) : 48 - 49
[3] Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis
Cools-Lartigue, Jonathan
Spicer, Jonathan
McDonald, Braedon
Gowing, Stephen
Chow, Simon
Giannias, Betty
Bourdeau, France
Kubes, Paul
Ferri, Lorenzo
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (08) : 3446 - 3458
[4] Inflammation and cancer
Coussens, LM
Werb, Z
[J]. NATURE, 2002, 420 (6917) : 860 - 867
[5] Relationship Between Lymphocytopenia and Circulating Tumor Cells as Prognostic Factors for Overall Survival in Metastatic Breast Cancer
De Giorgi, Ugo
Mego, Michal
Scarpi, Emanuela
Giuliano, Mario
Giordano, Antonio
Reuben, James M.
Valero, Vicente
Ueno, Naoto T.
Hortobagyi, Gabriel N.
Cristofanilli, Massimo
[J]. CLINICAL BREAST CANCER, 2012, 12 (04) : 264 - 269
[6] Lactate Dehydrogenase in Hepatocellular Carcinoma: Something Old, Something New
Faloppi, Luca
Bianconi, Maristella
Memeo, Riccardo
Gardini, Andrea Casadei
Giampieri, Riccardo
Bittoni, Alessandro
Andrikou, Kalliopi
Del Prete, Michela
Cascinu, Stefano
Scartozzi, Mario
[J]. BIOMED RESEARCH INTERNATIONAL, 2016, 2016
[7] The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
Faloppi, Luca
Scartozzi, Mario
Bianconi, Maristella
Baroni, Gianluca Svegliati
Toniutto, Pierluigi
Giampieri, Riccardo
Del Prete, Michela
De Minicis, Samuele
Bitetto, Davide
Loretelli, Cristian
D'Anzeo, Marco
Benedetti, Antonio
Cascinu, Stefano
[J]. BMC CANCER, 2014, 14
[8] Evolving strategies for the treatment of hepatocellular carcinoma: From clinical-guided to molecularly-taylored therapeutic options
Faloppi, Luca
Scartozzi, Mario
Maccaroni, Elena
Paolo, Marzia Di Pietro
Berardi, Rossana
Del Prete, Michela
Cascinu, Stefano
[J]. CANCER TREATMENT REVIEWS, 2011, 37 (03) : 169 - 177
[9] Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
Ferrucci, P. F.
Ascierto, P. A.
Pigozzo, J.
Del Vecchio, M.
Maio, M.
Cappellini, G. C. Antonini
Guidoboni, M.
Queirolo, P.
Savoia, P.
Mandala, M.
Simeone, E.
Valpione, S.
Altomonte, M.
Spagnolo, F.
Cocorocchio, E.
Gandini, S.
Giannarelli, D.
Martinoli, C.
[J]. ANNALS OF ONCOLOGY, 2016, 27 (04) : 732 - 738
[10] Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
Ferrucci, P. F.
Gandini, S.
Battaglia, A.
Alfieri, S.
Di Giacomo, A. M.
Giannarelli, D.
Cappellini, G. C. Antonini
De Galitiis, F.
Marchetti, P.
Amato, G.
Lazzeri, A.
Pala, L.
Cocorocchio, E.
Martinoli, C.
[J]. BRITISH JOURNAL OF CANCER, 2015, 112 (12) : 1904 - 1910

← 1 2 3 →